An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
Alnylam Pharmaceuticals (NASDAQ: ALNY) has launched the Alnylam Challengers program, committing $1 million to Acumen America to enhance health equity initiatives. This partnership aims to assist 75 million individuals in the U.S. by 2024 by tackling health disparities due to poverty and discrimination. The program includes a Social Investment Portfolio, an Advisory Corps for expert volunteering, and cross-sector Convenings to address health equity issues. Alnylam emphasizes its corporate responsibility and investment in sustainable health solutions.
Positive
Alnylam grants $1 million to support Acumen America in health equity initiatives.
Partnership aims to impact 75 million people in the U.S. by 2024.
Focus on innovative solutions addressing poverty and health access.
Negative
None.
− Alnylam will provide a $1Million Grant to Acumen America and will serve as an Anchor Partner of their Health Equity Portfolio –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of Alnylam Challengers, a signature community impact program that will support bold and diverse organizations in their pursuit of developing new and sustainable solutions to address challenges in health equity. Through this program, Alnylam will collaborate with social entrepreneurs, employees, and business partners to create innovative health solutions to tackle obstacles to accessing health care such as poverty, racial discrimination, and other social determinants of health.
Alnylam’s first U.S. partnership is with Acumen America, the U.S. division of a global nonprofit that raises philanthropic dollars and invests them in social impact-driven companies, leaders and ideas that take on world poverty. Alnylam is contributing $1 million to support Acumen America in its efforts to impact 75 million people in the U.S. by 2024.
“At Alnylam, corporate responsibility is a commitment to tackling unprecedented and complex challenges, taking courageous action, and using our business as a force for good. Alnylam Challengers is a multi-dimensional commitment for Alnylam,” said Dr. Pushkal Garg, Chief Medical Officer. “We are dedicated to the partnership aspect of this program – our employees, both as experts in their fields and as volunteers, are working with organizations, through our partnership with Acumen America, to enable their work, fuel growth and drive real change for the communities they serve.”
The three focus areas of Alnylam Challengers include:
Social Investment Portfolio: A strategic social investment model to tackle health inequities by partnering with a diverse and boldly innovative set of social entrepreneurs, enterprises, and non-profit organizations.
Advisory Corps: A skills-based volunteerism initiative where Alnylam employee teams serve as subject-matter expert (SME) advisors to address health equity issues through innovative business models.
Convenings: A series of cross-sector forums that embed Alnylam into industry, national, and international dialogue around pressing issues of health equity and rally others to think boldly and partner on important health issues.
“We are thrilled to be the first Alnylam Challengers partner to further our goal of empowering social entrepreneurs to address health equity,” said Catherine Casey Nanda, Acumen America Director. “Our approach centers on the idea of patient capital investing, which bridges the gap between the efficiency and scale of market-based approaches and the social impact of philanthropy.”
Alnylam’s Corporate Responsibility actions are organized across five interconnected, stakeholder-related focus areas: patients, science, employees, communities, and planet. Through Challengers, Alnylam is advancing its commitment to improve the health of humanity by investing in social organizations that are actively tackling the most pressing community and health equity challenges.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran), as well as Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.
Christine Regan Lindenboom (Investors and Media)
617-682-4340
Josh Brodsky (Investors)
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
FAQ
What is Alnylam Pharmaceuticals' recent initiative related to health equity?
Alnylam Pharmaceuticals has launched the Alnylam Challengers program, committing $1 million to Acumen America to tackle health equity issues.
How much funding did Alnylam provide to Acumen America?
Alnylam provided a $1 million grant to Acumen America.
What are the goals of the Alnylam Challengers program?
The Alnylam Challengers program aims to assist 75 million individuals in the U.S. by 2024 and address health disparities related to poverty and discrimination.
What are the focus areas of the Alnylam Challengers program?
The program includes a Social Investment Portfolio, an Advisory Corps for expert volunteering, and cross-sector Convenings to discuss health equity.
When is the target impact date for Alnylam's health equity program?
The target impact date for the program is by 2024.
